BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 9028341)

  • 1. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea.
    Steinberg MH; Lu ZH; Barton FB; Terrin ML; Charache S; Dover GJ
    Blood; 1997 Feb; 89(3):1078-88. PubMed ID: 9028341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of fetal hemoglobin response to hydroxyurea.
    Steinberg MH
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):8-14. PubMed ID: 9317196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.
    Charache S
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):15-21. PubMed ID: 9317197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reticulocyte parameters and hemoglobin F production in sickle cell disease patients undergoing hydroxyurea therapy.
    Borba R; Lima CS; Grotto HZ
    J Clin Lab Anal; 2003; 17(2):66-72. PubMed ID: 12640630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.
    Ware RE; Eggleston B; Redding-Lallinger R; Wang WC; Smith-Whitley K; Daeschner C; Gee B; Styles LA; Helms RW; Kinney TR; Ohene-Frempong K
    Blood; 2002 Jan; 99(1):10-4. PubMed ID: 11756146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease.
    Steinberg MH; Voskaridou E; Kutlar A; Loukopoulos D; Koshy M; Ballas SK; Castro O; Barton F
    Am J Hematol; 2003 Feb; 72(2):121-6. PubMed ID: 12555216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. The French Study Group on Sickle Cell Disease.
    Maier-Redelsperger M; de Montalembert M; Flahault A; Neonato MG; Ducrocq R; Masson MP; Girot R; Elion J
    Blood; 1998 Jun; 91(12):4472-9. PubMed ID: 9616141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia.
    Charache S; Dover GJ; Moore RD; Eckert S; Ballas SK; Koshy M; Milner PF; Orringer EP; Phillips G; Platt OS
    Blood; 1992 May; 79(10):2555-65. PubMed ID: 1375104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological impact of α genes, β haplotypes, and G6PD activity in sickle cell anemia at baseline and with hydroxyurea.
    Bernaudin F; Arnaud C; Kamdem A; Hau I; Lelong F; Epaud R; Pondarré C; Pissard S
    Blood Adv; 2018 Mar; 2(6):626-637. PubMed ID: 29555644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxyurea induction of hemoglobin F production in sickle cell disease: relationship between cytotoxicity and F cell production.
    Dover GJ; Humphries RK; Moore JG; Ley TJ; Young NS; Charache S; Nienhuis AW
    Blood; 1986 Mar; 67(3):735-8. PubMed ID: 2418898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.
    Steinberg MH; Barton F; Castro O; Pegelow CH; Ballas SK; Kutlar A; Orringer E; Bellevue R; Olivieri N; Eckman J; Varma M; Ramirez G; Adler B; Smith W; Carlos T; Ataga K; DeCastro L; Bigelow C; Saunthararajah Y; Telfer M; Vichinsky E; Claster S; Shurin S; Bridges K; Waclawiw M; Bonds D; Terrin M
    JAMA; 2003 Apr; 289(13):1645-51. PubMed ID: 12672732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia.
    Koshy M; Dorn L; Bressler L; Molokie R; Lavelle D; Talischy N; Hoffman R; van Overveld W; DeSimone J
    Blood; 2000 Oct; 96(7):2379-84. PubMed ID: 11001887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: The effect of hydroxyurea, fetal hemoglobin, and α-thalassemia.
    Ballas SK; Connes P;
    Eur J Haematol; 2018 Dec; 101(6):798-803. PubMed ID: 30204261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.
    el-Hazmi MA; al-Momen A; Kandaswamy S; Huraib S; Harakati M; al-Mohareb F; Warsy AS
    Acta Haematol; 1995; 94(3):128-34. PubMed ID: 7502628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea.
    Ma Q; Wyszynski DF; Farrell JJ; Kutlar A; Farrer LA; Baldwin CT; Steinberg MH
    Pharmacogenomics J; 2007 Dec; 7(6):386-94. PubMed ID: 17299377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy.
    Little JA; Hauser KP; Martyr SE; Harris A; Maric I; Morris CR; Suh JH; Taylor J; Castro O; Machado R; Kato G; Gladwin MT
    Eur J Haematol; 2009 Apr; 82(4):315-21. PubMed ID: 19215288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use.
    Green NS; Manwani D; Qureshi M; Ireland K; Sinha A; Smaldone AM
    Pediatr Blood Cancer; 2016 Dec; 63(12):2146-2153. PubMed ID: 27573582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spectrum of fetal hemoglobin responses in sickle cell patients treated with hydroxyurea: the National Institutes of Health experience.
    Rodgers GP
    Semin Oncol; 1992 Jun; 19(3 Suppl 9):67-73. PubMed ID: 1379375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxyurea attenuates activated neutrophil-mediated sickle erythrocyte membrane phosphatidylserine exposure and adhesion to pulmonary vascular endothelium.
    Haynes J; Obiako B; Hester RB; Baliga BS; Stevens T
    Am J Physiol Heart Circ Physiol; 2008 Jan; 294(1):H379-85. PubMed ID: 17993595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.